Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug

The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.

Photo: Jacob Ehrbahn/Politiken

by christian bundgaard, translated by catherine brett

Published: 18.05.22 at 07:44

There is a current shortage of Novo Nordisk’s fast-acting diabetes drug Novorapid 100 E/ml in Denmark, the Danish Medicines Agency has announced.

Novorapid is a subcutaneous form of fast-acting insulin aspart that is administered via injection pen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

Genmab to submit cancer candidate epcoritamab to the FDA before year-end

Foto: Tuala Hjarnø / Genmab / PR

The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.

Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again

The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.

Bavarian Nordic is working with EMA on monkeypox vaccine label expansion

Foto: Bavarian Nordic / PR

Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”

Coloplast's climate goals approved by international initiative

Foto: Coloplast / PR

The Science Based Targets initiative has approved Coloplast’s carbon emission reduction goals.

Top news from MedWatch this week

Miss anything?

Further reading

Related articles